Ipamorelin vs Mod-GRF (1-29).

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) belonging to the growth hormone-releasing peptide (GHRP) class, sometimes described as a "third-generation" GHRP. Derived from the earlier secretagogue GHRP-1, it acts as a ghrelin mimetic and was characterized by Novo Nordisk researchers in the late 1990s as the first GHRP-receptor agonist with selectivity for growth hormone (GH) release approaching that of GHRH. It has no approved therapeutic indication and exists as an investigational/research compound.

Mod GRF 1-29 (commonly sold as "CJC-1295 without DAC") is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH). It is the same tetra-substituted GHRH(1-29) peptide backbone used in CJC-1295, but it lacks the maleimido "Drug Affinity Complex" (DAC) linker that the long-acting form carries, so it behaves as a short-acting GHRH secretagogue. Its parent fragment, native GHRH(1-29) ("sermorelin"), retains essentially the full GH-releasing activity of the 44-residue hormone, and the four engineered substitutions are added to slow enzymatic breakdown.

Ipamorelin is a selective agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), the same G-protein-coupled receptor activated by the endogenous hormone ghrelin. Binding at the pituitary (and hypothalamus) triggers GH release through a GHRP-like pathway distinct from, but synergistic with, GHRH signaling; pharmacological profiling with GHRH and GHRP antagonists showed its action is mediated via the GHRP-type receptor rather than the GHRH receptor. Its defining feature is selectivity: in the original characterization it released GH with potency comparable to GHRP-6 but, unlike older GHRPs, did not meaningfully raise ACTH, cortisol, FSH, LH, prolactin, or TSH, even at doses far above the ED50 for GH release.

Like endogenous GHRH, the peptide binds the GHRH receptor on anterior-pituitary somatotrophs, raising intracellular cAMP and triggering pulsatile synthesis and release of growth hormone, which in turn drives hepatic IGF-1 production. The four amino-acid substitutions relative to native GHRH(1-29), typically described as D-Ala at position 2, Gln8, Ala15, and Leu27, are intended to resist degradation, with the D-alanine substitution at position 2 specifically blocking cleavage by dipeptidyl peptidase-IV (DPP-IV), the main enzyme that rapidly inactivates GHRH. Because it has no albumin-binding DAC tether, it is cleared quickly and is described as producing brief, pulse-like GH stimulation rather than the sustained "GH bleed" seen with the DAC version. It is mechanistically a secretagogue: it prompts the pituitary's own GH, rather than supplying GH directly.

The foundational evidence is preclinical: Raun et al. (Eur J Endocrinol, 1998) characterized ipamorelin in rats and isolated pituitary cells, establishing GH selectivity over ACTH/cortisol and other pituitary hormones. Subsequent animal work explored non-endocrine effects via GHS-R1a; for example, Venkova et al. (J Pharmacol Exp Ther, 2009) reported prokinetic/anti-ileus activity in a rodent model of postoperative ileus. The principal human data come from a single industry-sponsored (Helsinn Therapeutics) randomized, double-blind, placebo-controlled proof-of-concept trial in bowel-resection patients (Beck et al., Int J Colorectal Dis, 2014; ClinicalTrials.gov NCT00672074), where the primary composite gastrointestinal-recovery endpoint did not reach statistical significance, though some secondary measures trended favorably. There are no large, controlled human trials demonstrating efficacy for muscle growth, anti-aging, fat loss, bone density, or body composition in people; widely repeated claims in those areas rest on mechanism and animal data, not human outcome trials, and the postoperative-ileus program did not advance to Phase III.

The well-known human trials in this family, Teichman et al. (JCEM, 2006), Ionescu & Frohman (JCEM, 2006), and Sackmann-Sala et al. (Growth Horm IGF Res, 2009), all studied CJC-1295 WITH DAC, the long-acting albumin-binding version, not the no-DAC Mod GRF 1-29; Alba et al. (2006) used a GHRH-knockout mouse model. There is no robust, peer-reviewed human clinical trial of Mod GRF 1-29 (the no-DAC peptide) under that name establishing efficacy or safety, so claims about it are largely inferred from GHRH/sermorelin pharmacology and from the DAC-form data rather than directly tested. The unmodified parent peptide, sermorelin/GHRH(1-29), was an FDA-approved diagnostic and pediatric GH agent and is the best-characterized human reference point. Most published mentions of the no-DAC compound itself come from anti-doping analytical chemistry (e.g., Henninge et al., Drug Test Anal, 2010, identifying CJC-1295 in an illicit preparation), which characterize the molecule but not its clinical effects. Honest bottom line: the human-versus-preclinical gap is wide here, and the short-acting form is plausible by analogy but essentially unproven in controlled human studies.

Human safety data are limited to small, short-duration trials; the bowel-resection study used intravenous administration in a hospital setting and did not establish a long-term safety profile. As a GH/IGF-1-axis stimulant, plausible class-related concerns include effects on insulin sensitivity and blood glucose, fluid retention, and theoretical risks tied to chronically elevated GH/IGF-1 (e.g., relevant to people with cancer or active proliferative conditions), though these have not been well characterized for ipamorelin specifically in humans. Because much non-clinical material is produced as unregulated "research chemical" powder, real-world risks also include impurity, mislabeling, and lack of sterility/quality control. Long-term consequences of repeated use in humans are essentially unknown.

Documented safety data specific to Mod GRF 1-29 are minimal because controlled human trials of the no-DAC peptide are lacking; what is known is extrapolated from GHRH analogs broadly. In studies of related GHRH analogs and sermorelin, injection-site reactions (redness, swelling), flushing, and headache are the most commonly reported effects, and any sustained elevation of the GH/IGF-1 axis carries theoretical concerns including fluid retention, joint discomfort, insulin resistance/altered glucose handling, and uncertainty about long-term proliferative risk because IGF-1 is mitogenic. A major real-world hazard is that material sold under this name is research-grade and unregulated, so purity, identity, sterility, and contamination are not assured; anti-doping case reports document the compound appearing in mislabeled or "unknown" pharmaceutical preparations. Interactions with somatostatin tone, other secretagogues, and underlying endocrine or oncologic conditions are not well characterized, and long-term human safety is simply unknown.

Ipamorelin is not approved by the FDA (or other major regulators) for any indication; it remains an investigational/research-use compound and was the subject of FDA pharmacy-compounding review activity rather than drug approval. It is prohibited in sport by the World Anti-Doping Agency at all times as a growth hormone secretagogue under category S2 (Peptide Hormones, Growth Factors, and Mimetics).

Mod GRF 1-29 / CJC-1295 without DAC is not approved by the FDA or any major regulator for any indication and is an investigational/research-use-only compound; its unmodified parent, sermorelin, was previously FDA-approved but has been commercially discontinued. As a GHRH analog it falls under the World Anti-Doping Agency (WADA) Prohibited List class S2 (peptide hormones / growth factors and related substances) and is banned in sport at all times.